Cbl-b-IN-29
Cbl-b-IN-29 is an orally active CBL-B inhibitor. Cbl-b-IN-29 binds to the CBL-B active pocket. Cbl-b-IN-29 induces Jurkat cell release IL-2 with an EC50 of 159 nM, effectively inhibiting the function of immune E3 ubiquitin ligase. Cbl-b-IN-29 demonstrates robust anti-tumor efficacy in vivo with good tolerability and no observed adverse reactions. Cbl-b-IN-29 can be used for cancer immunotherapy, colorectal cancer and immune-oncology combination research.
For research use only. We do not sell to patients.
- CAS No.: 3070411-10-5
- Formula: C30H34FN5O
- Molecular Weight:499.62
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Cbl-b-IN-29 (compound 20) has a low risk for CYP inhibition/induction and hERG inhabitation[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:CT26 tumor cells (3×105)-induced BALB/c mice (6-8 weeks)[1]
-
Dosage:30 mg/kg
-
Administration:p.o., once daily for 15 days
-
Result:Resulted in a robust anti-tumor efficacy with a tumor growth inhibition (TGI) of 76%.
Indicated a low risk for CYP inhibition/induction and herg inhibition.
Exhibited good animal tolerability, with no observed adverse 412 reactions. .
Chemical Information
-
CAS No. 3070411-10-5
-
Molecular Weight 499.62
-
Formula C30H34FN5O
-
SMILES
CN1C([C@]2(C[C@@H](C)C2)C3=CC(C4=CC5=C(C([C@@H](C)NC6CCCC6)=CC=C5F)NC4=O)=CC=C3)=NN=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz